March 29, 2023 – FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada.
Read More from FACIT generates $1.5 billion in follow-on investment
March 23, 2023 – CTRL Therapeutics (“CTRL”) closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer.
Read More from CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer